1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Drugs In Development, 2022, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 7, 6 and 13 respectively.
Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Neutropenia - Overview
- Neutropenia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Neutropenia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Neutropenia - Companies Involved in Therapeutics Development
- Neutropenia - Drug Profiles
- Neutropenia - Dormant Projects
- Neutropenia - Discontinued Products
- Neutropenia - Product Development Milestones
- Featured News & Press Releases
- Mar 29, 2022: EMA recommends granting a marketing authorisation for stimufend
- Dec 08, 2021: Emendo Biotherapeutics to present new data at 63rd ASH Annual Meeting & Exhibition
- Dec 02, 2021: X4 Pharmaceuticals to host virtual seminar “Understanding Primary Immunodeficiencies” to highlight broadening market opportunities for mavorixafor
- Aug 03, 2021: X4 Pharmaceuticals announces key enrollment milestone achievements in ongoing mavorixafor clinical trials and reports second quarter financial results
- Oct 12, 2020: BeyondSpring forms partnership advisory committee comprised of industry veterans
- Sep 29, 2020: JAMA Oncology highlights plinabulin's efficacy in preventing chemotherapy-induced neutropenia as a monotherapy
- May 27, 2020: FDA accepts for review Fresenius Kabi’s first biosimilar regulatory submission for MSB11455, a biosimilar candidate of pegfilgrastim
- May 22, 2020: Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA
- Apr 28, 2020: Mylan and Biocon launch Fulphila, Biosimilar Pegfilgrastim, in Canada
- Apr 14, 2020: Biocon and Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Australia
- Nov 05, 2019: X4 Pharmaceuticals initiates phase 1b clinical trial of Mavorixafor for the treatment of severe Congenital Neutropenia
- Sep 23, 2019: BeyondSpring’s Plinabulin continues to build on superior product profile in breast cancer trial for neutropenia prevention
- Aug 23, 2019: BeyondSpring plinabulin demonstrates superior quality of life over pegfilgrastim in a head-to-head comparison trial for the prevention of neutropenia
- May 20, 2019: BeyondSpring abstract demonstrating bone pain benefit with lead asset, Plinabulin, versus Neulasta for neutropenia prevention Presented at ISPOR 2019
- May 16, 2019: BeyondSpring's rationale for the plinabulin-neulasta combination for neutropenia prevention accepted as abstracts at 2019 ASCO Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Neutropenia, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Neutropenia - Pipeline by Akthelia Pharmaceuticals Ltd, 2022
- Neutropenia - Pipeline by Aprilbio Co Ltd, 2022
- Neutropenia - Pipeline by BeyondSpring Inc, 2022
- Neutropenia - Pipeline by Biocon Ltd, 2022
- Neutropenia - Pipeline by Biocure Technology Inc, 2022
- Neutropenia - Pipeline by Biosidus SA, 2022
- Neutropenia - Pipeline by Biosimilar Solutions LLC, 2022
- Neutropenia - Pipeline by Cellerant Therapeutics Inc, 2022
- Neutropenia - Pipeline by CPL Biologicals Pvt Ltd, 2022
- Neutropenia - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, 2022
- Neutropenia - Pipeline by EmendoBio Inc, 2022
- Neutropenia - Pipeline by Genova Biotech Company Ltd, 2022
- Neutropenia - Pipeline by Ilkogen Ilac San Ve Tic AS, 2022
- Neutropenia - Pipeline by InflaRx NV, 2022
- Neutropenia - Pipeline by Lupin Ltd, 2022
- Neutropenia - Pipeline by Merck & Co Inc, 2022
- Neutropenia - Pipeline by Mycenax Biotech Inc, 2022
- Neutropenia - Pipeline by Phoenicia Biosciences Inc, 2022
- Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, 2022
- Neutropenia - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Neutropenia - Pipeline by Seres Therapeutics Inc, 2022
- Neutropenia - Pipeline by Shenzhen Xinpeng Bio-technology Co Ltd, 2022
- Neutropenia - Pipeline by Siam Bioscience Co Ltd, 2022
- Neutropenia - Pipeline by Statera Biopharma Inc, 2022
- Neutropenia - Pipeline by Tanvex BioPharma Inc, 2022
- Neutropenia - Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022
- Neutropenia - Pipeline by USV Pvt Ltd, 2022
- Neutropenia - Pipeline by X4 Pharmaceuticals Inc, 2022
- Neutropenia - Dormant Projects, 2022
- Neutropenia - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Neutropenia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akthelia Pharmaceuticals Ltd
- Aprilbio Co Ltd
- BeyondSpring Inc
- Biocon Ltd
- Biocure Technology Inc
- Biosidus SA
- Biosimilar Solutions LLC
- Cellerant Therapeutics Inc
- CPL Biologicals Pvt Ltd
- CSPC Pharmaceutical Group Ltd
- Dr. Reddy's Laboratories Ltd
- EmendoBio Inc
- Genova Biotech Company Ltd
- Ilkogen Ilac San Ve Tic AS
- InflaRx NV
- Lupin Ltd
- Merck & Co Inc
- Mycenax Biotech Inc
- Phoenicia Biosciences Inc
- Prolong Pharmaceuticals LLC
- Qilu Pharmaceutical Co Ltd
- Seres Therapeutics Inc
- Shenzhen Xinpeng Bio-technology Co Ltd
- Siam Bioscience Co Ltd
- Statera Biopharma Inc
- Tanvex BioPharma Inc
- Toko Pharmaceutical Industries Co Ltd
- USV Pvt Ltd
- X4 Pharmaceuticals Inc
